← Back to Screener
AtriCure, Inc. (ATRC)
Price$28.79
Favorite Metrics
Price vs S&P 500 (26W)-26.02%
Price vs S&P 500 (4W)-11.46%
Market Capitalization$1.51B
All Metrics
P/CF (Annual)26.27x
Book Value / Share (Quarterly)$9.88
P/TBV (Annual)4.43x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)17.39%
Cash Flow / Share (Quarterly)$0.85
Price vs S&P 500 (YTD)-31.15%
Gross Margin (TTM)74.98%
Net Profit Margin (TTM)-2.14%
EPS (TTM)$-0.24
10-Day Avg Trading Volume0.77M
EPS Excl Extra (TTM)$-0.24
Revenue Growth (5Y)20.95%
EPS (Annual)$-0.24
ROI (Annual)-2.04%
Gross Margin (Annual)74.98%
Net Profit Margin (5Y Avg)-3.03%
Cash / Share (Quarterly)$3.36
Revenue Growth QoQ (YoY)13.05%
ROA (Last FY)-1.75%
Revenue Growth TTM (YoY)14.88%
EBITD / Share (TTM)$-0.12
ROE (5Y Avg)-3.67%
Operating Margin (TTM)-1.77%
Cash Flow / Share (Annual)$0.85
P/B Ratio3.06x
P/B Ratio (Quarterly)4.00x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)2.63x
Net Interest Coverage (TTM)-6.26x
ROA (TTM)-1.84%
EV / EBITDA (TTM)21.57x
EPS Incl Extra (Annual)$-0.24
Current Ratio (Annual)3.96x
Quick Ratio (Quarterly)2.87x
3-Month Avg Trading Volume0.63M
52-Week Price Return-10.06%
EV / Free Cash Flow (Annual)33.30x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$8.92
P/S Ratio (Annual)2.82x
Asset Turnover (Annual)0.82x
52-Week High$43.18
Operating Margin (5Y Avg)-2.03%
EPS Excl Extra (Annual)$-0.24
CapEx CAGR (5Y)23.40%
Tangible BV CAGR (5Y)9.33%
26-Week Price Return-19.13%
Quick Ratio (Annual)2.87x
13-Week Price Return-30.56%
Total Debt / Equity (Annual)0.14x
Current Ratio (Quarterly)3.96x
Enterprise Value$1,408.104
Revenue / Share Growth (5Y)17.94%
Asset Turnover (TTM)0.86x
Book Value / Share Growth (5Y)1.65%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.74x
Pretax Margin (Annual)-1.90%
Cash / Share (Annual)$3.36
3-Month Return Std Dev45.96%
Gross Margin (5Y Avg)74.88%
Net Income / Employee (TTM)$-0
ROE (Last FY)-2.33%
Net Interest Coverage (Annual)-6.26x
EPS Basic Excl Extra (Annual)$-0.24
P/FCF (TTM)27.15x
Receivables Turnover (TTM)8.42x
EV / Free Cash Flow (TTM)33.30x
Total Debt / Equity (Quarterly)0.14x
EPS Incl Extra (TTM)$-0.24
Receivables Turnover (Annual)8.42x
ROI (TTM)-2.12%
P/S Ratio (TTM)2.82x
Pretax Margin (5Y Avg)-2.88%
Revenue / Share (Annual)$11.19
Tangible BV / Share (Annual)$8.92
Forward P/E383.87x
Price vs S&P 500 (52W)-44.69%
Year-to-Date Return-27.22%
5-Day Price Return-2.07%
EPS Normalized (Annual)$-0.24
ROA (5Y Avg)-2.77%
Net Profit Margin (Annual)-2.14%
Month-to-Date Return0.91%
Cash Flow / Share (TTM)$-0.24
EBITD / Share (Annual)$-0.12
Operating Margin (Annual)-1.77%
LT Debt / Equity (Annual)0.13x
P/CF (TTM)26.27x
ROI (5Y Avg)-3.18%
LT Debt / Equity (Quarterly)0.13x
EPS Basic Excl Extra (TTM)$-0.24
P/TBV (Quarterly)4.43x
P/B Ratio (Annual)4.00x
Inventory Turnover (TTM)1.74x
Pretax Margin (TTM)-1.90%
Book Value / Share (Annual)$9.88
Price vs S&P 500 (13W)-32.94%
Beta1.33x
P/FCF (Annual)35.63x
Revenue / Share (TTM)$11.15
ROE (TTM)-2.43%
52-Week Low$27.26
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.27
4.27
4.07
4.07
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
ATRCAtriCure, Inc. | 2.82x | 20.95% | 74.98% | -1.77% | $28.79 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
AtriCure develops surgical solutions for treating atrial fibrillation, managing left atrial appendage, and alleviating post-operative pain in cardiac and thoracic procedures. Its product portfolio includes cryoablation, radiofrequency ablation, and nerve pain management technologies used in open-heart and minimally invasive surgical settings. The company sells through direct sales and distributors, with the majority of revenue from the United States.